Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

[1]  D. Sargent,et al.  Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. , 2018, European journal of cancer.

[2]  C. Punt,et al.  From tumour heterogeneity to advances in precision treatment of colorectal cancer , 2017, Nature Reviews Clinical Oncology.

[3]  S. Barni,et al.  Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[4]  V. Heinemann,et al.  The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. , 2017, European journal of cancer.

[5]  M. V. van Oijen,et al.  Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. , 2016, European journal of cancer.

[6]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  V. Heinemann,et al.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[9]  I. Nagtegaal,et al.  Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies , 2014, Clinical Cancer Research.

[10]  Shuji Ogino,et al.  Colorectal cancer: a tale of two sides or a continuum? , 2012, Gut.

[11]  Daniel J Sargent,et al.  The ARCAD clinical trials program: an update and invitation. , 2012, The oncologist.

[12]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[13]  H. Lenz,et al.  Gender Disparities in Metastatic Colorectal Cancer Survival , 2009, Clinical Cancer Research.

[14]  F. Kabbinavar,et al.  Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk , 2008, Oncology.

[15]  D. Sargent,et al.  Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Julian de Meyrick,et al.  The Delphi method and health research , 2003 .

[18]  C. Webb,et al.  The Delphi technique: a methodological discussion. , 1994, Journal of advanced nursing.

[19]  Richard Hacker.  The Delphi technique , 1988 .

[20]  C Duffield,et al.  The Delphi technique. , 1988, The Australian journal of advanced nursing : a quarterly publication of the Royal Australian Nursing Federation.